21 results
424B3
CHRO
Chromocell Therapeutics Corp.
15 May 24
Prospectus supplement
4:21pm
ended March 31, 2023, the fair value of each stock option granted was estimated using the Black-Scholes Option Pricing Model using the following
424B3
CHRO
Chromocell Therapeutics Corp.
15 May 24
Prospectus supplement
4:15pm
ended March 31, 2023, the fair value of each stock option granted was estimated using the Black-Scholes Option Pricing Model using the following
10-Q
2024 Q1
CHRO
Chromocell Therapeutics Corp.
15 May 24
Quarterly report
4:06pm
option granted was estimated using the Black-Scholes Option Pricing Model using the following inputs:
Exercise price
Expected dividend yield
Risk
424B3
CHRO
Chromocell Therapeutics Corp.
16 Apr 24
Prospectus supplement
5:49pm
, and will vest over 3 years.
During the year ended December 31, 2023, the fair value of each stock option granted was estimated using the Black-Scholes Option
424B3
CHRO
Chromocell Therapeutics Corp.
16 Apr 24
Prospectus supplement
5:45pm
, and will vest over 3 years.
During the year ended December 31, 2023, the fair value of each stock option granted was estimated using the Black-Scholes Option
10-K
ileajdibw3sok43
16 Apr 24
Annual report
4:48pm
424B4
lb6reg vnlkxa
20 Feb 24
Prospectus supplement with pricing info
5:30pm
424B4
ndafb4a
20 Feb 24
Prospectus supplement with pricing info
5:28pm